Clinical trials: Etoposide, completed
Small Cell Lung Cancer, Extensive Stage Lung Cancer
Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small cell lung cancer, or SCLC, constitutes approximately 15% of the 170,000 new cases of lung cancer diagnosed annually in the United States.
- Conditions
- Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
- Trial name
- NCT00856830
- Testing
- Novel Drug Combination
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Neuroblastoma
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00025428
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 100 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Leukemia, Myeloid, Acute
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
- Trial name
- NCT02306291
- Testing
- GMI-1271, Mitoxantrone, Etoposide
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlycoMimetics Incorporated
Philadelphia Positive Acute Lymphoblastic Leukemia
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together…
- Trial name
- NCT01724879
- Testing
- Dasatinib
- Where
- 22 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Goethe University
Myeloma, Plasma-Cell, Lymphoma, Malignant
Multi-day Doses in Prevention of Nausea and Emesis
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational…
- Trial name
- NCT00600353
- Testing
- Palonosetron, Aprepitant, Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth…
- Trial name
- NCT00667342
- Testing
- Bevacizumab, Cisplatin, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Rationale/Purpose: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01117441
- Testing
- PEG-L-asparaginase, cyclophosphamide, cytarabine
- Where
- 139 sites in Australia, Austria and 5 more
- Volunteers
- 6,136 people
- Sponsor
- University Hospital Schleswig-Holstein
SCLC,Extensive Stage
Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance
To validate the predictive value of transcriptome-based molecular subtyping of extensive stage small cell lung cancer (SCLC) for the efficacy of programmed death-1(PD-1)/programmed death-ligand1(PD-L1) inhibitor in the first line…
- Trial name
- MOSAIC (NCT05933863)
- Testing
- PD-(L)1 antibody immunotherapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and using drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002691
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
The investigators developed a protocol utilizing once-daily intravenous busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).
- Trial name
- BME (NCT03792815)
- Testing
- Busulfan, Melphalan, Etoposide
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Soonchunhyang University Hospital
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003625
- Testing
- cyclosporine, etoposide, vincristine sulfate
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Lymphoma
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003421
- Testing
- bleomycin sulfate, ABVD regimen, chlorambucil
- Where
- 2 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Lymphoma
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
- Trial name
- OPTIMAL (NCT00117598)
- Testing
- Temsirolimus (CCI-779), Investigator's choice
- Where
- 73 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Pfizer
Retinoblastoma, Retinal Neoplasm
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain.
- Trial name
- NCT00186888
- Testing
- Enucleation, Vincristine, Carboplatin, Focal Therapies
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML.
- Trial name
- NCT00703820
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- 8 sites in United States, Singapore
- Volunteers
- 324 people
- Sponsor
- St. Jude Children's Research Hospital
Effect of Drug, Drug
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Conditions
- Effect of Drug, Drug, Toxicity
- Trial name
- OAIE (NCT05277480)
- Testing
- Apatinib+IE, IE
- Where
- 5 sites in China
- Volunteers
- 81 people
- Sponsor
- Peking University People's Hospital
Small Cell Lung Cancer Limited Stage, Radiotherapy
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC
This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the…
- Trial name
- TRISS (NCT03214003)
- Testing
- SIB, Standard
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Anhui Shi, MD
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of R-(-)-gossypol acetic acid when given together with cisplatin and etoposide in treating patients with advanced solid tumors or extensive stage small cell lung…
- Trial name
- NCT00544596
- Testing
- R-(-)-gossypol acetic acid, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
This randomized phase II trial studies cisplatin and etoposide to see how well they work when given with or without Hedgehog inhibitor GDC-0449 (vismodegib) or IGF-1R MOAB IMC-A12 (cixutumumab) in treating patients with…
- Trial name
- NCT00887159
- Testing
- Cisplatin, Cixutumumab, Etoposide
- Where
- 301 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)